Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member printed answering member label
tabling member	label

Search

1127317

	registered interest
	date	17/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Young People
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the number of young people developing bowel cancer.
	tabling member constituency	Coventry South
	tabling member printed	Mr Jim Cunningham
	uin	255652
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>Obesity and poor diet are risk factors for bowel cancer in young people.</p><p>The second chapter of the world-leading childhood obesity plan was published in June 2018. This builds on the real progress made since the publication of chapter one in 2016, particularly in reformulation of the products our children eat and drink most. In chapter two we have set a bold ambition to halve childhood obesity by 2030 and significantly reduce the gap in obesity between children from the most and least deprived areas by 2030.</p><p>Many of the measures in both chapters of the plan will have an impact on tackling obesity across all age groups. These include the soft drinks industry levy, sugar reduction and wider calorie reformulation programme, restricting promotions and calorie labelling in restaurants which will improve our eating habits and reduce the amount of sugar we consume.</p><p>‘Childhood obesity: a plan for action, chapter 2’ is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/childhood-obesity-a-plan-for-action-chapter-2" target="_blank">www.gov.uk/government/publications/childhood-obesity-a-plan-for-action-chapter-2</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:24:08 answering member 4455 label Biography information for Seema Kennedy
	tabling member	308 label Biography information for Mr Jim Cunningham

1127327

	registered interest
	date	17/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diffuse Intrinsic Pontine Glioma
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of access to NHS support for sufferers of diffuse intrinsic pontine glioma.
	tabling member constituency	Sheffield, Brightside and Hillsborough
	tabling member printed	Gill Furniss
	uin	255692
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>No specific assessment has been made by the Department at this time.</p><p>Care for children with Diffuse Intrinsic Pontine Glioma (DIPG) is co-ordinated and provided by Children’s Cancer Principal Treatment Centres (PTCs) working in conjunction with Paediatric Oncology Shared Care Units. Children’s Cancer PTCs are responsible for planning and delivering treatment for children with DIPG as well as ensuring these children can access wider support services such as psychology services, specialist play services and other therapies.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:25:19 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4571 label Biography information for Gill Furniss

1127168

	registered interest
	date	16/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Urinary Tract Infections
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce unplanned hospital admissions resulting from urinary tract infections.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	255355
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>In England, it is the responsibility of National Health Service commissioners to make decisions on individual treatments for urinary tract infections on the basis of the available evidence, taking into account guidance from the National Institute for Health and Care Excellence (NICE) where available. NICE guidance is always evidence based, adhering to the latest clinical thinking and research to determine the best treatment for patients.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:26:35 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4523 label Biography information for Catherine West

1127170

	registered interest
	date	16/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Urinary Tract Infections
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to improve the (a) reporting and (b) tracking of urinary tract infections in the NHS; and if he will make a statement.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	255357
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>NHS Digital’s Hospital Episodes Statistics publishes data on finished consultant episodes with a primary or secondary diagnosis of urinary tract infection broken down by financial year, rather than by calendar year.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:28:15 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4523 label Biography information for Catherine West

1127283

	registered interest
	date	17/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage fairer pricing by pharmaceutical companies for drugs supplied to the NHS.
	tabling member constituency	Coventry South
	tabling member printed	Mr Jim Cunningham
	uin	255651
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The 2019 Voluntary Scheme for Branded Medicines Pricing and Access, and the statutory scheme for branded medicines pricing, work together to control the cost of branded medicines to the National Health Service and ensure it stays within affordable limits.</p><p> </p><p>The 2019 Voluntary Scheme began on 1 January 2019 and will run for five years until the end of 2023. The Voluntary Scheme aims to provide stability and predictability for all parties in terms of the United Kingdom’s branded medicines expenditure and the medicines pricing and access environment for the period 2019 to 2023. It also aims to achieve a balance between patient access, affordability and supporting the development of innovative new medicines, including support for small companies.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:30:06 answering member 4455 label Biography information for Seema Kennedy
	tabling member	308 label Biography information for Mr Jim Cunningham

1127289

	registered interest
	date	16/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Prices
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the affordability of medicines as a result of the redrafted WHO resolution entitled, Improving the transparency of markets for medicines, vaccines and other health-related technologies proposed by Italy on 29 April 2019.
	tabling member constituency	Liverpool, Walton
	tabling member printed	Dan Carden
	uin	255695
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:32:11 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4651 label Biography information for Dan Carden

1125505

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what analyses they have conducted of the risks and benefits of reducing the infant pneumococcal vaccination schedule from 2+1 to 1+1; and whether they will publish the results any such analyses.
	tabling member printed	Baroness Masham of Ilton
	uin	HL15600
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15599 question first answered 22/05/2019 14:50:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf title JCVI Minute 2015
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1125504

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the recommendations by the Joint Committee on Vaccination and Immunisation to reduce the infant pneumococcal vaccination schedule from three doses to two.
	tabling member printed	Baroness Masham of Ilton
	uin	HL15599
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15600 question first answered 22/05/2019 14:50:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf title JCVI Minute 2015
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1125506

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps they are taking to improve vaccination coverage for people living with HIV.
	tabling member printed	Baroness Masham of Ilton
	uin	HL15601
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>Public Health England, in partnership with NHS England and the Department, is taking steps to improve vaccination coverage in England, including for people living with HIV.</p><p>These steps include initiatives to improve access to the immunisation programme; communication with the public; data to identify underserved individuals and populations; and training for healthcare professionals, changes to vaccination eligibility criteria; launching disease elimination strategies; running targeted social media campaigns; providing information leaflets in multiple languages and running e-learning programme for healthcare practitioners.</p><p>Certain vaccines are delivered through sexual health services that particularly benefit people living with HIV. This includes vaccines for hepatitis A, hepatitis B and human papillomavirus. People living with HIV are in the influenza risk groups and are invited for the flu vaccine on an annual basis.</p> answering member printed Baroness Blackwood of North Oxford question first answered 22/05/2019 14:50:46 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1126321

	registered interest
	date	13/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gender Dysphoria: Children
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they intend to publish the results of the research project started in 2011 by the NHS Gender Identity Development Service Early pubertal suppression in a carefully selected group of adolescents with gender identity disorder; and if not, whether they will arrange for the data gathered by that study to be made available to other researchers.
	tabling member printed	Lord Lucas
	uin	HL15681
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The research is an ethically approved study being carried out by the Tavistock and Portman NHS Foundation Trust since 2011, which is the largest provider of services for the alleviation of gender dysphoria in the United Kingdom.</p><p>The study will evaluate early pubertal suppression in a carefully selected group of adolescents with a clinical diagnosis of gender dysphoria. There are 44 young people taking part in the study.</p><p>The Tavistock and Portman NHS Foundation Trust has plans to publish the data <ins class="ministerial">on the blocker and cross-sex hormones, for those who were appropriate for this, as</ins><del class="ministerial">once</del> all of the young people in the study have reached <ins class="ministerial">this</ins><del class="ministerial">the</del> stage<ins class="ministerial">.</ins> <del class="ministerial">when a clinical decision is made about moving from pubertal suppressants to cross-sex hormones, which the Trust expects to occur in the next 12 months.</del></p> answering member printed Baroness Blackwood of North Oxford question first answered 22/05/2019 14:51:30 question first ministerially corrected 31/07/2019 15:30:59 answering member 4019 label Biography information for Baroness Blackwood of North Oxford previous answer version 119577 answering member printed Baroness Blackwood of North Oxford answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1879 label Biography information for Lord Lucas